What is Pharmazz?
Pharmazz, Inc., established in 2010 and headquartered in Willowbrook, Illinois, is a biopharmaceutical firm dedicated to pioneering novel treatments for critical care and neurological conditions. With a global operational footprint, including a subsidiary in India, Pharmazz leverages its expertise to advance therapeutic solutions. The company's focus on unmet medical needs in complex disease areas positions it as a key player in the biopharmaceutical landscape, attracting substantial investment for its research and development initiatives.
How much funding has Pharmazz raised?
Pharmazz has raised a total of $40M across 2 funding rounds:
Private Equity
$15M
Private Equity
$25M
Private Equity (2024): $15M with participation from Sun Pharma
Private Equity (2025): $25M led by Sun Pharma
Key Investors in Pharmazz
Sun Pharma
Sun Pharma is a leading specialty generic pharmaceutical company based in Mumbai, India, known for manufacturing and distributing a wide range of pharmaceutical formulations and active pharmaceutical ingredients. Their investment in Pharmazz suggests a strategic interest in innovative therapies within the biopharmaceutical sector.
What's next for Pharmazz?
The recent major strategic investment signals a pivotal phase for Pharmazz, likely enabling the acceleration of its drug development programs and the expansion of its clinical trial activities. This infusion of capital is expected to bolster its efforts in bringing innovative therapies to market, particularly in the critical care and neurological disorder segments. Pharmazz's strategic financing suggests a strong outlook for scaling operations and potentially pursuing further partnerships or market entries, reinforcing its commitment to addressing significant healthcare challenges.
See full Pharmazz company page
